Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19.,Expert Review of Clinical Immunology

当前位置： X-MOL 学术 › Expert Rev. Clin. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19.
Expert Review of Clinical Immunology ( IF 4.4 ) Pub Date : 2020-08-11 , DOI: 10.1080/1744666x.2020.1792778
Sebastian E Sattui ₁ , Jean W Liew ₂ , Elizabeth R Graef ₃ , Ariella Coler-Reilly ₄ , Francis Berenbaum ₅ , Alí Duarte-García ₆ , Carly Harrison ₇ , Maximilian F Konig ₈ , Peter Korsten ₉ , Michael S Putman ₁₀ , Philip C Robinson ₁₁ , Emily Sirotich _{12,

13} , Manuel F Ugarte-Gil ₁₄ , Kate Webb _{15,

16} , Kristen J Young ₁₇ , Alfred H J Kim ₁₈ , Jeffrey A Sparks ₁₉

Affiliation

Division of Rheumatology, Department of Medicine, Hospital for Special Surgery , New York, NY, USA.
Division of Rheumatology, Department of Medicine, University of Washington , Seattle, WA, USA.
Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, USA.
Division of Rheumatology, Department of Medicine, Washington University School of Medicine , St. Louis, MO, USA.
Department of Rheumatology, Sorbonne University, INSERM CRSA, AP-HP , Paris, France.
Division of Rheumatology, Mayo Clinic , Rochester, MN, USA.
LupusChat , New York, NY, USA.
Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine , Baltimore, MD, USA.
Department of Nephrology and Rheumatology, University Medical Center Göttingen , Göttingen, Germany.
Department of Medicine, Northwestern University , Chicago, IL, USA.
University of Queensland Faculty of Medicine , Brisbane, Australia.
Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, ON, Canada.
Canadian Arthritis Patient Alliance , Toronto, ON, Canada.
School of Medicine, Universidad Científica Del Sur and Hospital Nacional Guillermo Almenara Irigoyen , EsSalud, Lima, Peru.
Department of Paediatric Rheumatology, University of Cape Town , Cape Town, South Africa.
Francis Crick Institute , London, UK.
Division of Rheumatic Diseases, UT Southwestern Medical Center , Dallas, TX, USA.
Division of Rheumatology, Department of Medicine, Washington University School of Medicine , Saint Louis, MO, USA.
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School , Boston, MA, USA.

Introduction

Several months into the COVID-19 pandemic, safe and effective treatments against this global health disaster have yet to be identified. Clinical research trials around the world are underway testing a wide array of possible medications. In particular, the off-label use of hydroxychloroquine for COVID-19 prophylaxis and treatment has created many unprecedented challenges for the scientific community and the public.

Areas covered

We critically assessed major events from February – May 2020 that contributed to widespread use of hydroxychloroquine for the treatment and prophylaxis of COVID-19. We aimed to explore how opinions toward hydroxychloroquine may shift from early enthusiasm (based on in vitro and preliminary clinical data) to the hope for a miracle cure (through communication and promotion of questionable results) and, finally, to a rise of skepticism as more in-depth analyses are emerging.

Expert opinion

Mindful and rigorous acquisition of data, as well as its interpretation, are essential to an effective pandemic response. The rapid and premature promotion of results has had major implications for global crisis management, even creating distrust among the public. It is crucial for the medical and scientific community to incorporate the lessons learned from this situation.

中文翻译：